Leucovorin-induced resistance against FDH growth suppressor effects occurs through DHFR up-regulation.
10-Formyltetrahydrofolate dehydrogenase (FDH) converts 10-formyltetrahydrofolate to tetrahydrofolate (THF). Expression of the enzyme in FDH-deficient cancer cells induces cytotoxicity that can be reversed by supplementation with high concentrations of a reduced folate, 5-formyl-THF (leucovorin). In contrast, non-tumor cells are resistant to FDH. The present study was undertaken to investigate mechanisms that could protect cells against FDH suppressor effects. Using 10 microM leucovorin supplementation of FDH-sensitive A549 cells transfected for FDH expression, we selected clones that have acquired resistance against FDH. Resistant cells expressed high levels of FDH and were capable of growing after withdrawal of leucovorin. These cells, however, have increased doubling time due to prolonged S phase. They also have significantly increased levels of total folate pool and THF/5,10-methylene-THF pool while the level of 10-formyl-THF was two-fold lower than in parental FDH-sensitive cells. We have shown that the FDH-catalyzed reaction proceeds at about a three-fold slower rate at the ratio of 10-formyl-THF/THF corresponding to the resistant cells than at the ratio corresponding to parental sensitive cells, due to product inhibition (KI is 2.35 microM). FDH-resistant cells have strongly up-regulated dihydrofolate reductase (DHFR) that is proposed to be a mechanism for the alteration of folate pools and a key component of the acquired resistance. Elevation of DHFR in A549 cells by transient transfection decreased sensitivity to FDH toxicity and allowed selection of FDH-resistant clones. DHFR-induced repression of FDH catalysis could be an S phase-related metabolic adjustment that provides protection against FDH suppressor effects.
Oleinik
Natalia V
NV
Department of Biochemistry and Molecular Biology, Medical University of South Carolina, 173 Ashley Avenue, P.O. Box 250509, Charleston, SC 29425, United States.
Krupenko
Natalia I
NI
Reuland
Steven N
SN
Krupenko
Sergey A
SA
D001483:Base Sequence; D002384:Catalysis; D002460:Cell Line; D017931:DNA Primers; D004351:Drug Resistance; D005492:Folic Acid / Q000378:metabolism; D006801:Humans; D002955:Leucovorin / Q000494:pharmacology*; D000587:Oxidoreductases Acting on CH-NH Group Donors / Q000037:antagonists & inhibitors*; D013762:Tetrahydrofolate Dehydrogenase / Q000378:metabolism*; D015854:Up-Regulation / Q000187:drug effects*; D000099295:Formyltetrahydrofolate Dehydrogenase
D017931:DNA Primers; D005492:Folic Acid; D002955:Leucovorin; D000587:Oxidoreductases Acting on CH-NH Group Donors; D013762:Tetrahydrofolate Dehydrogenase; D000099295:Formyltetrahydrofolate Dehydrogenase